News
TLTFF
0.167
-2.39%
-0.004
Weekly Report: what happened at TLTFF last week (0601-0605)?
Weekly Report · 06/08 09:32
Theralase warrants to start trading on TSXV June 9 under TLT.WT
PUBT · 06/03 11:17
Weekly Report: what happened at TLTFF last week (0525-0529)?
Weekly Report · 06/01 09:34
Theralase Q1 FY26 net loss narrows 29.9% to C$1.03 million; revenue rises 45% to C$132,634
PUBT · 05/29 21:19
Theralase Technologies Inc. reports Q1 results
Seeking Alpha · 05/29 21:12
Theralase(R) Releases Q1 2026 Financial Statements
Newsfile · 05/29 21:04
Weekly Report: what happened at TLTFF last week (0518-0522)?
Weekly Report · 05/25 09:36
Theralase closes C$4.76 million private placement at C$0.24 per unit
PUBT · 05/22 21:21
Theralase(R) Closes C$4.8 Million Offering
Newsfile · 05/20 15:06
Weekly Report: what happened at TLTFF last week (0511-0515)?
Weekly Report · 05/18 09:36
Theralase prices up to C$4 million private placement at C$0.24 per unit
PUBT · 05/13 16:28
Weekly Report: what happened at TLTFF last week (0504-0508)?
Weekly Report · 05/11 09:34
Theralase(R) Announces $4 Million Brokered LIFE Offering
Newsfile · 05/05 23:10
Theralase FY25 net loss narrows to CAD 4.12 million; revenue drops 21% to CAD 816,468
PUBT · 05/04 21:38
Theralase Technologies Inc. reports FY results
Seeking Alpha · 05/04 21:37
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Newsfile · 05/04 21:22
Weekly Report: what happened at TLTFF last week (0427-0501)?
Weekly Report · 05/04 09:34
Weekly Report: what happened at TLTFF last week (0420-0424)?
Weekly Report · 04/27 09:34
Weekly Report: what happened at TLTFF last week (0413-0417)?
Weekly Report · 04/20 09:33
Theralase plans Phase 0/I/II adaptive trial of X-ray-activated Rutherrin in MIBC
PUBT · 04/13 11:11
More
Webull provides a variety of real-time TLTFF stock news. You can receive the latest news about Theralase Technologies Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLTFF
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.